Ex vivo activation characterization and targeting of the latent HIV infected reservoir to cure HIV

Ex vivo activation characterization and targeting of the latent HIV infected reservoir to cure HIV - EX VIVO

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54790

Enrollment

150

Registered

2013-02-11

Start date

2013-09-03

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Latent HIV infection

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 years or older. 2. Confirmed HIV infectie

Exclusion criteria

Exclusion criteria: 1. Inability to place 2.5 cm venous catheter or perform phlebotomy 2. Major comorbidities: A. Severe symptomatic anemia B. Recent symptomatic cardiovascular event. 3. The inability to participate due to any other relevant medical, social, environmental, psychological, factors or according to the HIV treating physician*s judgement.

Design outcomes

Primary

Measure	Time frame
The following endpoints refer to in vitro experiments: 1. Descriptive analysis of latently infected HIV sub-populations of PBMC*s, by use of flow cytometry. 2. Quantify increases transcription related factors before and after the addition of HIV expression modulating agents. 3. To quantify the virologic response of latent HIV infected reservoir to treatment by HIV expression modulating agents. 4. To explore potential biomarkers of the size of the HIV reservoir. These include cytokines (IFNg, IL1beta, IL2, IL4, IL6, IL8, IL10, IL-12p70, IL13, TNFalfa etc), HLA phenotyping (HLA B27 and B57), amount of HIV specific broadly neutralizing antibodies, SOMAscan (proteomics) level of HIV specific CTL activation and CD4+ T cel responses. 5. Prospective clinical cohort 6. Differences in HIV reservoir, shock and kill strategies, and immunity between different HIV clinical phenotypes	—

Measure

Time frame

The following endpoints refer to in vitro experiments: 1. Descriptive analysis of latently infected HIV sub-populations of PBMC*s, by use of flow cytometry. 2. Quantify increases transcription related factors before and after the addition of HIV expression modulating agents. 3. To quantify the virologic response of latent HIV infected reservoir to treatment by HIV expression modulating agents. 4. To explore potential biomarkers of the size of the HIV reservoir. These include cytokines (IFNg, IL1beta, IL2, IL4, IL6, IL8, IL10, IL-12p70, IL13, TNFalfa etc), HLA phenotyping (HLA B27 and B57), amount of HIV specific broadly neutralizing antibodies, SOMAscan (proteomics) level of HIV specific CTL activation and CD4+ T cel responses. 5. Prospective clinical cohort 6. Differences in HIV reservoir, shock and kill strategies, and immunity between different HIV clinical phenotypes

—

Countries

Netherlands

Outcome results